What is BioScience Health Innovations Inc's earnings per share (EPS)?

BioScience Health Innovations Inc (BHICD) reported diluted earnings per share of $0.06 for fiscal year 2025. This represents a 500.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BioScience Health Innovations Inc (BHICD) Financials

BHICD

Trailing 12 months to March 31, 2026

Revenue $5.2M +86.5% YoY

Net Income -$15K -102.6% YoY

EPS (Diluted) $0.06 FY2025 annual

Operating Cash Flow -$708K -277.3% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BHICD SEC filings page.

BioScience Health Innovations Inc (BHICD) reported $5.2M in revenue over the twelve months to Mar 31, 2026, up 86.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BHICD FY2025 2026-08-30

Rapid scale is converting sales into operating leverage, while weaker cash conversion reveals heavier working-capital demands.

Year over year, revenue more than tripled to $5.7M while gross margin fell to 57.0%, showing scale arrived with cost or mix pressure rather than simple margin preservation. Operating margin nevertheless improved, yet net income converted into only a fraction of operating cash flow as receivables and inventory absorbed cash—an earnings-to-cash mismatch that scale alone does not explain.

The cost structure is doing more work than gross margin suggests: SG&A rose to $2.2M, but consumed a smaller share of revenue, lifting operating margin to 12.6%. This supports operating leverage, not proof that underlying unit economics improved.

Equity moved from negative to $1.5M positive, while debt-to-equity remained low at 0.2x; the business is now funded more by equity than obligations. However, operating cash flow was only $172K against $642K of net income, so reported profitability is not yet translating proportionally into internally generated cash.

Financial Health Signals

Financial health score not available

BioScience Health Innovations Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

5/7

BioScience Health Innovations Inc passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.27x

For every $1 of reported earnings, BioScience Health Innovations Inc generates $0.27 in operating cash flow ($172K OCF vs $642K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$751K

YoY-38.8%

QoQ-52.3%

BioScience Health Innovations Inc generated $751K in revenue in Q1 2026. This represents a decrease of 38.8% from the same quarter a year earlier. Against the prior quarter it is down 52.3%.

Net Income

-$230K

YoY-153.9%

QoQ+1.6%

BioScience Health Innovations Inc reported -$230K in net income in Q1 2026. This represents a decrease of 153.9% from the same quarter a year earlier. Against the prior quarter it is up 1.6%.

EPS (Diluted)

-$0.02

BioScience Health Innovations Inc earned -$0.02 per diluted share (EPS) in Q1 2026.

EBITDA

Not reported for Q1 2026.

Cash & Balance Sheet

Cash & Debt

$1.1M

YoY+11.3%

QoQ+73.0%

5Y CAGR+243.8%

BioScience Health Innovations Inc held $1.1M in cash as of Q1 2026; long-term debt is not reported for that period.

Shares Outstanding

11M

QoQ+3.5%

5Y CAGR+15.8%

BioScience Health Innovations Inc had 11M shares outstanding in Q1 2026. Against the prior quarter it is up 3.5%.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Gross Margin

64.7%

YoY-8.4pp

QoQ+28.3pp

BioScience Health Innovations Inc's gross margin was 64.7% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is down 8.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 28.3 percentage points.

Operating Margin

-30.6%

YoY-65.4pp

QoQ-20.7pp

BioScience Health Innovations Inc's operating margin was -30.6% in Q1 2026, reflecting core business profitability. This is down 65.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 20.7 percentage points.

Net Margin

-30.6%

YoY-65.4pp

QoQ-15.8pp

BioScience Health Innovations Inc's net profit margin was -30.6% in Q1 2026, showing the share of revenue converted to profit. This is down 65.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 15.8 percentage points.

Return on Equity

-13.7%

YoY-47.5pp

QoQ+2.2pp

BioScience Health Innovations Inc's ROE was -13.7% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is down 47.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.2 percentage points.

Capital Allocation

R&D Spending

$50K

YoY+32.5%

BioScience Health Innovations Inc invested $50K in research and development in Q1 2026. This represents an increase of 32.5% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

BHICD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BHICD quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20
Revenue	$5.2M	$5.7M+208.3%	$1.8M+208.7%	$598K+761.8%	$69K	$0	$0
Cost of Revenue	$2.4M	$2.4M+356.6%	$536K+373.6%	$113K+1067.0%	$10K	N/A	N/A
Gross Profit	$2.8M	$3.2M+147.6%	$1.3M+170.2%	$484K+712.2%	$60K	N/A	N/A
R&D Expenses	N/A	$38K+44.9%	$26K	$0	N/A	N/A	N/A
SG&A Expenses	$2.4M	$2.2M+92.5%	$1.1M+62.3%	$706K+366.7%	$151K+490.9%	$26K+233.4%	$8K
Operating Income	$62K	$719K+726.5%	$87K+134.6%	-$252K-47.6%	-$170K-565.6%	-$26K-233.4%	-$8K
Interest Expense	N/A	N/A	N/A	N/A	N/A	$450	N/A
Income Tax	N/A	$77K	$0	$0	$0	$0	$0
Net Income	-$15K	$642K+638.0%	$87K+134.6%	-$252K-47.6%	-$170K-565.6%	-$26K-233.4%	-$8K
EPS (Basic)	N/A	$0.06+500.0%	$0.01+200.0%	-$0.01	N/A	N/A	N/A
EPS (Diluted)	—	$0.06+500.0%	$0.01	-$0.01	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	11M+4.5%	11M	34M	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'25	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Revenue	$751K-38.8%	$1.6M+157.7%	$1.1M+97.5%	$1.8M+357.5%	$1.2M+342.0%	$610K+101.0%	$573K+198.2%	$384K+453.0%
Cost of Revenue	$265K-19.8%	$1.0M+269.0%	$433K+192.2%	$683K+825.5%	$331K+672.5%	$271K+304.1%	$148K+365.8%	$74K+676.9%
Gross Profit	$486K-45.8%	$572K+68.7%	$698K+64.4%	$1.1M+246.2%	$896K+281.7%	$339K+43.3%	$425K+164.9%	$310K+417.6%
R&D Expenses	$50K+32.5%	N/A	N/A	N/A	$38K+4563.4%	N/A	N/A	N/A
SG&A Expenses	$626K+44.3%	$656K+118.6%	$577K+67.0%	$540K+142.6%	$434K+55.8%	$300K+13.3%	$345K+64.2%	$223K+60.5%
Operating Income	-$230K-153.9%	-$157K-1673.5%	-$9K-115.6%	$458K+516.7%	$427K+899.5%	$10K+125.9%	$56K+198.3%	$74K+187.1%
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Net Income	-$230K-153.9%	-$234K-2446.4%	-$9K-115.6%	$458K+516.7%	$427K+899.5%	$10K+125.9%	$56K+198.3%	$74K+187.1%
EPS (Basic)	-$0.02-300.0%	N/A	$0.00-100.0%	$0.01	$0.01	N/A	$0.01	$0.00
EPS (Diluted)	-$0.02	N/A	$0.00	$0.01	$0.01	N/A	$0.01	$0.00
Diluted Shares (Avg)	11M	N/A	11M	44M+5.5%	44M+7.1%	N/A	11M-73.0%	42M

Not reported in any period shown, so not listed: EBITDA, Interest Expense.

BHICD Balance Sheet

BHICD quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20
Total Assets	$1.7M+95.4%	$874K+835.7%	$93K+195.5%	$32K+400.6%	$6K-69.4%	$21K
Current Assets	$1.6M+83.9%	$848K+807.8%	$93K+195.5%	$32K+400.6%	$6K-69.4%	$21K
Cash & Equivalents	$662K-0.1%	$663K+3343.8%	$19K+66.3%	$12K+468.5%	$2K-90.1%	$21K
Inventory	$336K+476.7%	$58K+54.7%	$38K+207.1%	$12K	N/A	N/A
Accounts Receivable	$399K+298.1%	$100K+175.1%	$36K+369.6%	$8K	N/A	N/A
Total Liabilities	$230K+496.3%	$39K-61.5%	$100K+105.3%	$49K+155.4%	$19K+144.6%	$8K
Total Equity	$1.5M+76.9%	$835K+12455.6%	-$7K+60.7%	-$17K-34.3%	-$13K-199.8%	$13K
Retained Earnings	$301K+188.3%	-$341K+20.3%	-$428K-142.4%	-$177K-416.4%	-$34K-298.4%	-$9K

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'25	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Total Assets	$2.3M+67.0%	$1.7M+95.4%	$2.1M+397.1%	$2.1M+863.2%	$1.4M+801.1%	$874K+835.7%	$416K+337.7%	$214K+239.2%
Current Assets	$2.2M+63.9%	$1.6M+83.9%	$2.0M+388.0%	$2.0M+829.5%	$1.3M+764.9%	$848K+807.8%	$409K+330.3%	$214K+239.2%
Cash & Equivalents	$1.1M+11.3%	$662K-0.1%	$1.1M+241.9%	$1.3M+802.9%	$1.0M+1006.5%	$663K+3343.8%	$333K+693.6%	$144K+374.7%
Inventory	$874K+305.4%	$336K+476.7%	$758K+1694.0%	$249K+512.1%	$216K+433.5%	$58K+54.7%	$42K+23.1%	$41K+156.5%
Accounts Receivable	$78K-16.2%	$399K+298.1%	$63K+98.1%	$390K+1311.6%	$93K+336.0%	$100K+175.1%	$32K+70.5%	$28K+74.7%
Total Liabilities	$646K+385.8%	$230K+496.3%	$356K+681.9%	$338K+1277.6%	$133K+232.8%	$39K-61.5%	$46K-47.3%	$25K-79.1%
Total Equity	$1.7M+33.5%	$1.5M+76.9%	$1.7M+362.1%	$1.7M+809.5%	$1.3M+998.8%	$835K+12455.6%	$370K+4204.6%	$189K+448.5%
Retained Earnings	$71K-17.1%	$301K+188.3%	$535K+252.3%	$543K+233.4%	$86K+117.8%	-$341K+20.3%	-$351K+9.9%	-$407K-22.5%

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill, Current Liabilities, Non-Current Liabilities, Long-Term Debt.

BHICD Cash Flow Statement

BHICD quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20
Operating Cash Flow	-$708K	$172K+642.5%	$23K+107.5%	-$308K-68.4%	-$183K-520.9%	-$29K-283.2%	-$8K
Stock-Based Compensation	N/A	N/A	N/A	$0-100.0%	$225	N/A	N/A
Investing Cash Flow	-$27K	-$57K-118.3%	-$26K	$0	$0	N/A	$0
Financing Cash Flow	$852K	-$116K-117.9%	$646K+104.8%	$316K+62.4%	$194K+1691.1%	$11K-61.7%	$28K

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'25	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Operating Cash Flow	-$552K-268.2%	-$101K-100.2%	-$340K-751.8%	$285K+311.3%	$328K+783.4%	-$50K+10.9%	$52K+174.2%	$69K+160.6%
Investing Cash Flow	$0+100.0%	-$11K+43.2%	$0+100.0%	-$16K	-$30K	-$19K	-$7K	$0
Financing Cash Flow	$1.0M+1433.2%	-$366K-191.8%	$180K+25.2%	$2K+111.6%	$68K-44.5%	$399K+1082.5%	$144K+75.6%	-$18K-113.5%

Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

BHICD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BHICD quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20
Gross Margin	57.0%-14.0pp	70.9%-10.1pp	81.1%-4.9pp	86.0%	N/A	N/A
Operating Margin	12.6%+7.9pp	4.7%+46.8pp	-42.1%	-245.8%	N/A	N/A
Net Margin	11.3%+6.6pp	4.7%+46.8pp	-42.1%	-245.8%	N/A	N/A
Return on Equity	43.5%+33.0pp	10.4%	N/A	N/A	N/A	-59.9%
Return on Assets	37.6%+27.6pp	10.0%+279.3pp	-269.3%+269.9pp	-539.3%-133.7pp	-405.6%-368.4pp	-37.2%
Debt-to-Equity	0.16+0.1x	0.05	N/A	N/A	N/A	0.61
Asset Turnover	3.33+1.2x	2.11-4.3x	6.40+4.2x	2.19+2.2x	0.000.0x	0.00

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'25	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Gross Margin	64.7%-8.4pp	36.4%-19.2pp	61.7%-12.4pp	61.1%-19.6pp	73.0%-11.5pp	55.6%-22.3pp	74.1%-9.3pp	80.8%-5.5pp
Operating Margin	-30.6%-65.4pp	-10.0%-11.6pp	-0.8%-10.6pp	26.0%+6.7pp	34.8%+54.0pp	1.6%+14.3pp	9.8%+39.6pp	19.3%
Net Margin	-30.6%-65.4pp	-14.8%-16.5pp	-0.8%-10.6pp	26.0%+6.7pp	34.8%+54.0pp	1.6%+14.3pp	9.8%+39.6pp	19.3%
Return on Equity	-13.7%-47.5pp	-15.8%-17.0pp	-0.5%-15.7pp	26.6%-12.6pp	33.8%+80.3pp	1.2%	15.2%+679.5pp	39.3%
Return on Assets	-9.9%-40.5pp	-13.7%-14.8pp	-0.4%-13.9pp	22.3%-12.5pp	30.6%+65.1pp	1.1%+42.2pp	13.5%+73.7pp	34.8%+170.2pp
Debt-to-Equity	0.38+0.3x	0.16+0.1x	0.21+0.1x	0.20+0.1x	0.11-0.2x	0.05	0.12-9.9x	0.13
Asset Turnover	0.32-0.6x	0.92+0.2x	0.55-0.8x	0.85-0.9x	0.88-0.9x	0.70-2.6x	1.38-0.6x	1.80+0.7x

Not reported in any period shown, so not listed: Current Ratio, FCF Margin.

Where BioScience Health Innovations Inc Ranks

Frequently Asked Questions

What is BioScience Health Innovations Inc's annual revenue?

BioScience Health Innovations Inc (BHICD) reported $5.7M in total revenue for fiscal year 2025. This represents a 208.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BioScience Health Innovations Inc's revenue growing?

BioScience Health Innovations Inc (BHICD) revenue grew by 208.3% year-over-year, from $1.8M to $5.7M in fiscal year 2025.

Is BioScience Health Innovations Inc profitable?

Yes, BioScience Health Innovations Inc (BHICD) reported a net income of $642K in fiscal year 2025, with a net profit margin of 11.3%.

What is BioScience Health Innovations Inc's gross margin?

BioScience Health Innovations Inc (BHICD) had a gross margin of 57.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is BioScience Health Innovations Inc's operating margin?

BioScience Health Innovations Inc (BHICD) had an operating margin of 12.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is BioScience Health Innovations Inc's net profit margin?

BioScience Health Innovations Inc (BHICD) had a net profit margin of 11.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is BioScience Health Innovations Inc's return on equity (ROE)?

BioScience Health Innovations Inc (BHICD) has a return on equity of 43.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is BioScience Health Innovations Inc's operating cash flow?

BioScience Health Innovations Inc (BHICD) generated $172K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are BioScience Health Innovations Inc's total assets?

BioScience Health Innovations Inc (BHICD) had $1.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does BioScience Health Innovations Inc spend on research and development?

BioScience Health Innovations Inc (BHICD) invested $38K in research and development during fiscal year 2025.

How many shares does BioScience Health Innovations Inc have outstanding?

BioScience Health Innovations Inc (BHICD) had 11M shares outstanding as of fiscal year 2025.

What is BioScience Health Innovations Inc's debt-to-equity ratio?

BioScience Health Innovations Inc (BHICD) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is BioScience Health Innovations Inc's return on assets (ROA)?

BioScience Health Innovations Inc (BHICD) had a return on assets of 37.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is BioScience Health Innovations Inc's Piotroski F-Score?

BioScience Health Innovations Inc (BHICD) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BioScience Health Innovations Inc's earnings high quality?

BioScience Health Innovations Inc (BHICD) has an earnings quality ratio of 0.27x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.